Ligand Pharmaceuticals (LGND) Other Operating Expenses (2010 - 2026)

Ligand Pharmaceuticals has reported Other Operating Expenses for 16 years, with the latest figure at $11.4 million in Q1 2026.

• Quarterly Other Operating Expenses fell 10.21% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.2 million (up 3.66% YoY) and the FY2023 annual result came in at $2.1 million, changed N/A from the prior year.
• Other Operating Expenses eased to $11.4 million in Q1 2026 per LGND's latest filing, from $17.3 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $37.7 million in Q2 2024 and troughed at $2.1 million in Q3 2023.
• A 5-year average of $13.8 million and a median of $12.3 million in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses soared 268.87% in 2024, then sank 66.96% in 2025.
• Over 5 years, Other Operating Expenses stood at $13.3 million in 2022, then sank by 84.03% to $2.1 million in 2023, then surged by 1675.29% to $37.7 million in 2024, then tumbled by 54.1% to $17.3 million in 2025, then sank by 34.22% to $11.4 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $11.4 million, $17.3 million, and $11.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.